NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics.The combined unit will operate as NeuroBo Pharmaceuticals with NeuroBo shareholders holding a 96.24% stake in the firm.
Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high triglycerides—setting up a phase 3 program.